Takahiro Ebata

Takahiro Ebata

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

DNA methylation microarray analysis of human DNA samples contaminated with mouse DNA.

DNA methylation microarray analysis of human DNA samples contaminated with mouse DNA.

Journal: Epigenomics
Published: April 30, 2026

Clinical features and impact of p53 status on sporadic mismatch repair deficiency and Lynch syndrome in uterine cancer.

Clinical features and impact of p53 status on sporadic mismatch repair deficiency and Lynch syndrome in uterine cancer.

Journal: Cancer science
Published: October 12, 2023

HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity.

HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity.

Journal: Breast cancer research and treatment
Published: April 07, 2023

DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer.

DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer.

Journal: Gynecologic oncology
Published: March 15, 2022

A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors.

A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors.

Journal: Cancer chemotherapy and pharmacology
Published: January 26, 2022

DNA methylation marker to estimate ovarian cancer cell fraction.

DNA methylation marker to estimate ovarian cancer cell fraction.

Journal: Medical oncology (Northwood, London, England)
Published: October 14, 2021

Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents.

Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: June 02, 2020

Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies.

Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies.

Journal: Cancer chemotherapy and pharmacology
Published: May 29, 2020

Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.

Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.

Journal: Oncology
Published: March 02, 2020

DMPK is a New Candidate Mediator of Tumor Suppressor p53-Dependent Cell Death.

DMPK is a New Candidate Mediator of Tumor Suppressor p53-Dependent Cell Death.

Journal: Molecules (Basel, Switzerland)
Published: August 08, 2019

Improved survival among patients enrolled in oncology phase 1 trials in recent decades.

Improved survival among patients enrolled in oncology phase 1 trials in recent decades.

Journal: Cancer chemotherapy and pharmacology
Published: July 26, 2019

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.

Journal: Investigational new drugs
Published: March 01, 2019
Showing 1-12 of 29

Last Updated: 09/26/2026